ProMIS Neurosciences

ProMIS Neurosciences Inc., a clinical-stage biotechnology company, was founded in 2004 and has since established headquarters in Toronto, Canada, and Cambridge, Massachusetts. The company, formerly known as Amorfix Life Sciences Ltd., changed its name in July 2015 and trades on the NASDAQ under the ticker PMN. At its core, ProMIS is dedicated to discovering and developing antibody therapies for neurodegenerative conditions like Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD).

The company's scientific foundation is built upon the research of co-founder Dr. Neil Cashman, who serves as the Chief Scientific Officer. Dr. Cashman, a Professor Emeritus at the University of British Columbia, is a physician and scientist specializing in neurodegenerative diseases with a research focus on protein misfolding. His work has led to the development of ProMIS's proprietary computational discovery platforms, ProMIS™ and EpiSelect™. These AI-driven engines use a physics and algorithmic approach to predict and identify unique targets, known as Disease Specific Epitopes (DSEs), that appear only on the surface of toxic, misfolded proteins.

This precision targeting is the company's key differentiator. The technology enables the creation of antibodies that selectively bind to and clear harmful protein oligomers—the root cause of several neurodegenerative diseases—without affecting the healthy, functional forms of the same proteins. This selectivity is designed to offer greater efficacy and enhanced safety, potentially avoiding side effects like brain swelling and bleeding (ARIA) seen with other therapies. The business model centers on advancing its pipeline through clinical trials, securing strategic partnerships with other pharmaceutical companies, and licensing its technology platform. Revenue generation is anticipated from the commercialization of its therapeutic antibodies.

The company's lead product candidate, PMN310, is a monoclonal antibody targeting toxic amyloid-beta (Aβ) oligomers for the treatment of Alzheimer's disease. In July 2025, the U.S. FDA granted Fast Track designation to PMN310, highlighting its potential to address a critical unmet need. ProMIS is advancing PMN310 in its PRECISE-AD Phase 1b clinical trial. Beyond Alzheimer's, the pipeline includes PMN267 for ALS, which targets misfolded TDP-43 protein, and PMN442, which targets toxic alpha-synuclein oligomers for Parkinson's disease and multiple system atrophy. The company is also developing vaccines, such as PMN311 for AD and PMN440 for synucleinopathies.

Keywords: neurodegenerative diseases, antibody therapeutics, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, protein misfolding, toxic oligomers, PMN310, Dr. Neil Cashman, EpiSelect, precision medicine, clinical-stage biotechnology, monoclonal antibody, neuroinflammation, amyloid-beta, alpha-synuclein, TDP-43, Fast Track designation, neurotherapeutics, computational drug discovery, disease specific epitopes